Stifel raises Disc Medicine stock target to $94, maintains Buy
Stifel analysts increased their price target for Disc Medicine (NASDAQ:IRON) shares to $94.00, up from the previous $90.00. Currently trading at $57.07 with a market capitalization of $1.7 billion, ...
Kennebec Journal3dOpinion
Opinion: How four anonymous strangers saved my life
By the third day, the dizziness had made it impossible for me to walk unaided. I couldn’t sit upright without toppling over.
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/2 ...
Too Old to Operate4d
Continuous Glucose Monitoring Can Predict Microvascular Complications in Type 1 Diabetes
Fourteen-day continuous glucose monitoring (CGM) traces added to Diabetes Control and Complications Trial (DCCT) data can ...
FierceBiotech5d
Novo Nordisk gets BACH1, inking IMMvention deal to orchestrate attack on sickle cell disease
Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...
IMMvention Therapeutix Enters Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases
IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...